Investors purchased shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading on Tuesday. $258.41 million flowed into the stock on the tick-up and $222.17 million flowed out of the stock on the tick-down, for a money net flow of $36.24 million into the stock. Of all stocks tracked, Gilead Sciences had the 6th highest net in-flow for the day. Gilead Sciences traded down ($1.60) for the day and closed at $78.17

Several equities research analysts have recently commented on GILD shares. Zacks Investment Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Oppenheimer Holdings Inc. restated a “buy” rating and set a $116.00 price target (down from $120.00) on shares of Gilead Sciences in a report on Wednesday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a report on Saturday, May 14th. Robert W. Baird restated a “buy” rating on shares of Gilead Sciences in a report on Monday, May 16th. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Sunday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $106.82.

The stock has a market capitalization of $102.83 billion and a price-to-earnings ratio of 6.84. The firm’s 50 day moving average is $81.86 and its 200 day moving average is $87.05.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period in the prior year, the firm earned $3.15 EPS. Gilead Sciences’s revenue for the quarter was down 5.7% compared to the same quarter last year. Equities analysts expect that Gilead Sciences Inc. will post $11.78 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.41%. The ex-dividend date is Wednesday, September 14th.

In other news, CEO John F. Milligan sold 112,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $86.94, for a total transaction of $9,737,280.00. Following the sale, the chief executive officer now owns 1,170,963 shares in the company, valued at $101,803,523.22. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the sale, the chairman now owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The disclosure for this sale can be found here.

A number of large investors have made changes to their positions in GILD. Pekin Singer Strauss Asset Management IL boosted its stake in shares of Gilead Sciences by 3.3% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 12,681 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 400 shares in the last quarter. Azimuth Capital Management LLC boosted its stake in shares of Gilead Sciences by 195.0% in the fourth quarter. Azimuth Capital Management LLC now owns 12,894 shares of the biopharmaceutical company’s stock valued at $1,305,000 after buying an additional 8,523 shares in the last quarter. TrimTabs Asset Management LLC boosted its stake in shares of Gilead Sciences by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 19,871 shares of the biopharmaceutical company’s stock valued at $2,011,000 after buying an additional 369 shares in the last quarter. Aviance Capital Partners LLC boosted its stake in shares of Gilead Sciences by 5.4% in the fourth quarter. Aviance Capital Partners LLC now owns 29,997 shares of the biopharmaceutical company’s stock valued at $3,035,000 after buying an additional 1,527 shares in the last quarter. Finally, Sawtooth Asset Management Inc. boosted its stake in shares of Gilead Sciences by 521.2% in the fourth quarter. Sawtooth Asset Management Inc. now owns 31,037 shares of the biopharmaceutical company’s stock valued at $3,141,000 after buying an additional 26,041 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.